BRPI0813809A2 - derivados de 7-alquinil -1,8-naftiridonas, sua preparação e sua aplicação em terapêutica. - Google Patents

derivados de 7-alquinil -1,8-naftiridonas, sua preparação e sua aplicação em terapêutica. Download PDF

Info

Publication number
BRPI0813809A2
BRPI0813809A2 BRPI0813809A BRPI0813809A BRPI0813809A2 BR PI0813809 A2 BRPI0813809 A2 BR PI0813809A2 BR PI0813809 A BRPI0813809 A BR PI0813809A BR PI0813809 A BRPI0813809 A BR PI0813809A BR PI0813809 A2 BRPI0813809 A2 BR PI0813809A2
Authority
BR
Brazil
Prior art keywords
alkyl group
therapy
preparation
application
naphthyridones
Prior art date
Application number
BRPI0813809A
Other languages
English (en)
Inventor
Alam Antoine
Bono Françoise
Mccort Gary
Duclos Olivier
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0813809A2 publication Critical patent/BRPI0813809A2/pt
Publication of BRPI0813809B1 publication Critical patent/BRPI0813809B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)

Abstract

derivados de 7-alquinil -1,8-naftiridonas, sua preparação e sua aplicação em terapêutica a presente invenção refere-se aos compostos correspondentes à fórmula (1): na qual: r1 e r2 representam, independentemente um do outro: um átomo de hidrogênio, um grupo alquila em c1-c7 eventualmente substituído por um ou vários grupos alcóxi, r3 representa um grupo alquila em c1-c7; r4 representa um átomo de hidrogênio, um grupo alquila em c1-c4; y representa um grupo alcóxi em c1-c4, um grupo -nrr', -o(ch2)n- c(o)- nrr', no qual r e r' são tais como definidos abaixo e n é um número inteiro igual a 1 ou 2; r" representa um grupo alquila em c1-c4; e r e r' representam independentemente um do outro um átomo de hidrogênio, um grupo -co-alquila em c1-c4 ou um grupo -coor", no qual r", tal como definido acima. processo de preparação e aplicação em terapêutica.
BRPI0813809-5A 2007-06-13 2008-06-11 Compostos derivados de 7-alquinil-1,8-naftiridonas, seu processo de preparação, seu uso, composição farmacêutica, medicamento e combinação BRPI0813809B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0704193 2007-06-13
FR0704193A FR2917413B1 (fr) 2007-06-13 2007-06-13 Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
PCT/FR2008/000794 WO2009007536A2 (fr) 2007-06-13 2008-06-11 Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique

Publications (2)

Publication Number Publication Date
BRPI0813809A2 true BRPI0813809A2 (pt) 2020-02-04
BRPI0813809B1 BRPI0813809B1 (pt) 2021-05-25

Family

ID=38961501

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813809-5A BRPI0813809B1 (pt) 2007-06-13 2008-06-11 Compostos derivados de 7-alquinil-1,8-naftiridonas, seu processo de preparação, seu uso, composição farmacêutica, medicamento e combinação

Country Status (28)

Country Link
US (2) US8263614B2 (pt)
EP (1) EP2158194B1 (pt)
JP (1) JP5346337B2 (pt)
KR (1) KR20100019507A (pt)
CN (1) CN101815715B (pt)
AR (1) AR066955A1 (pt)
AT (1) ATE509923T1 (pt)
AU (1) AU2008274100B2 (pt)
BR (1) BRPI0813809B1 (pt)
CA (1) CA2690349C (pt)
CO (1) CO6150157A2 (pt)
CY (1) CY1111748T1 (pt)
DK (1) DK2158194T3 (pt)
EA (1) EA016552B1 (pt)
ES (1) ES2366629T3 (pt)
FR (1) FR2917413B1 (pt)
HR (1) HRP20110550T1 (pt)
IL (1) IL202677A (pt)
IN (1) IN2009KN04279A (pt)
MA (1) MA31674B1 (pt)
ME (1) ME00957B (pt)
MX (1) MX2009013514A (pt)
MY (1) MY146939A (pt)
NZ (1) NZ581883A (pt)
PL (1) PL2158194T3 (pt)
PT (1) PT2158194E (pt)
SI (1) SI2158194T1 (pt)
WO (1) WO2009007536A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2917412B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
EP2249831A2 (en) 2007-12-10 2010-11-17 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2954943B1 (fr) * 2010-01-07 2013-03-01 Sanofi Aventis Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
US20130210733A1 (en) * 2010-06-17 2013-08-15 Cytokinetics, Inc. Methods of treating lung disease
WO2013072882A1 (en) * 2011-11-18 2013-05-23 Actelion Pharmaceuticals Ltd 2 -amino- 1, 8 -naphthyridine-3 -carboxamide derivatives as antimicrobial agents
CN116509854B (zh) * 2023-04-26 2025-05-23 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） 一种萘啶酮衍生物的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11510156A (ja) 1995-08-02 1999-09-07 カイロサイエンス・リミテッド キノロン類およびその医療上の使用
CN1156476C (zh) 1998-01-29 2004-07-07 第一三得利制药株式会社 作为ⅳ型磷酸二酯酶抑制剂的1-环烷基-1,8-二氮杂萘-4-酮衍生物
DE19826050A1 (de) * 1998-06-12 1999-12-16 Bayer Ag Verfahren zur Herstellung von Chinolon- und Naphthyridoncarbonsäuren und deren Ester
JP2004528379A (ja) 2001-05-08 2004-09-16 シエーリング アクチエンゲゼルシャフト Ｖｅｇｆｒ−２およびｖｅｇｆｒ−３インヒビターとしての選択的アントラニルアミドピリジンアミド
AU2002257459B2 (en) 2001-05-24 2006-12-14 Merck Frosst Canada Ltd 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
US7148357B2 (en) 2002-07-31 2006-12-12 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
JP2008501628A (ja) * 2004-06-02 2008-01-24 武田薬品工業株式会社 インドール誘導体およびがんの治療用途
FR2917412B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
US20100144782A1 (en) 2010-06-10
FR2917413A1 (fr) 2008-12-19
MA31674B1 (fr) 2010-09-01
HRP20110550T1 (hr) 2011-09-30
EA016552B1 (ru) 2012-05-30
EA201070010A1 (ru) 2010-06-30
FR2917413B1 (fr) 2009-08-21
BRPI0813809B1 (pt) 2021-05-25
JP2010529179A (ja) 2010-08-26
WO2009007536A8 (fr) 2010-01-07
NZ581883A (en) 2011-05-27
ME00957B (me) 2012-06-20
JP5346337B2 (ja) 2013-11-20
ATE509923T1 (de) 2011-06-15
MX2009013514A (es) 2010-01-27
MY146939A (en) 2012-10-15
CN101815715A (zh) 2010-08-25
CN101815715B (zh) 2014-10-08
US8586602B2 (en) 2013-11-19
HK1143590A1 (en) 2011-01-07
PL2158194T3 (pl) 2011-10-31
SI2158194T1 (sl) 2011-10-28
US20120238598A1 (en) 2012-09-20
IN2009KN04279A (pt) 2015-08-28
EP2158194B1 (fr) 2011-05-18
ES2366629T3 (es) 2011-10-24
WO2009007536A2 (fr) 2009-01-15
PT2158194E (pt) 2011-08-17
KR20100019507A (ko) 2010-02-18
AU2008274100A1 (en) 2009-01-15
CO6150157A2 (es) 2010-04-20
EP2158194A2 (fr) 2010-03-03
WO2009007536A3 (fr) 2009-03-19
CY1111748T1 (el) 2015-10-07
IL202677A0 (en) 2010-06-30
IL202677A (en) 2014-12-31
AR066955A1 (es) 2009-09-23
CA2690349A1 (fr) 2009-01-15
CA2690349C (fr) 2015-11-24
US8263614B2 (en) 2012-09-11
DK2158194T3 (da) 2011-09-12
AU2008274100B2 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
BRPI0813809A2 (pt) derivados de 7-alquinil -1,8-naftiridonas, sua preparação e sua aplicação em terapêutica.
CY1124357T1 (el) Προσδιορισμος ανισορροπιας αλληλουχιας νουκλεϊκων οξεων
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
CY1112201T1 (el) Φαρμακο για τη θεραπευτικη αγωγη γριπης
EA201171328A1 (ru) Производное замещенного изохинолина
BRPI1007456A2 (pt) derivados de azaespiranil-alquilcarbamatos de compostos heterocíclicos com 5 membros, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0510598A (pt) compostos de amida de aril ou heteroaril substituìdos
EA200870192A1 (ru) Новые серосодержащие производные циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ
MX2009002802A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas, su preparacion y su aplicacion en terapeutica.
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
DOP2011000061A (es) Compuestos de pirrol
MY177250A (en) Novel nicotinamide derivative or salt thereof
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
GEP201706728B (en) Noxious organism control agent
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
BRPI0911476A2 (pt) compostos ativadores de glicoquinase de piridazinona, composição farmaceutica, uso dos compostos, método para tratamento de uma enfermidade e/ou distúbio metabólico e processo para a preparação dos compostos
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
NO20050134L (no) Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse
BR112014031969A2 (pt) derivados de pirimidinona como agentes antimaláricos
RU2015122032A (ru) Оксазолидинонсодержащие соединения, композиции и способы их использования
MX2010003983A (es) 5,6-diarilpiridinas sustituidas en la posicion 2 y 3, su preparacion y su uso terapeutico.
EA200970497A1 (ru) Производные пиррола, их получение и их применение в терапии

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/06/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF